The ABCB1 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human cervical carcinoma line Ca Ski, engineered to disrupt the ABCB1 gene (Homo sapiens). This polyclonal model provides a heterogeneous loss-of-function system for the ATP-binding cassette subfamily B member 1 locus, avoiding clonal artifacts while ensuring robust gene disruption and loss of P-glycoprotein (P-gp) expression. It serves as a defined experimental platform for investigating multidrug resistance and chemosensitivity.
The Ca Ski cell line is an adherent epithelial line derived from a metastatic cervical epidermoid carcinoma and is widely used as a cervical cancer model. These cells harbor HPV16 sequences, express E6/E7 oncoproteins, and exhibit tumorigenic properties such as deregulated proliferation and impaired apoptosis. The Ca Ski background is particularly relevant for studying drug resistance in cervical carcinoma, providing a disease-pertinent context for ABCB1 knockout studies.
ABCB1 encodes P-glycoprotein, a 170-kDa ATP-dependent efflux transporter that exports structurally diverse xenobiotics and chemotherapeutics, reducing intracellular concentrations and conferring multidrug resistance. Transcriptionally, ABCB1 is regulated by nuclear receptors PXR (NR1I2) and CAR (NR1I3), often in complex with RXR??, and is modulated by stress-responsive factors p53, HIF-1??, and NF-??B, as well as Wnt/??-catenin and PI3K/Akt signaling. P-gp resides in lipid rafts, interacts with HSP90, and effluxes substrates such as doxorubicin, paclitaxel, and vinblastine. In this knockout model, ABCB1 disruption eliminates P-gp activity, enhancing intracellular drug retention.
Multidrug resistance due to P-gp overexpression limits chemotherapy efficacy in cervical cancer. The ABCB1 Knockout Ca Ski Polyclonal Cells enable dissection of P-gp-dependent resistance mechanisms and screening of chemosensitizers in an isogenic cervical carcinoma background. Loss of drug efflux activity reveals chemosensitivity profiles and facilitates preclinical evaluation of agents designed to circumvent resistance. The polyclonal composition better reflects tumor heterogeneity, strengthening translational applicability.
This model supports mechanistic studies of multidrug resistance, drug screening for P-gp substrates, and chemosensitizer evaluation. Key assays include drug sensitivity measurements (MTT, CellTiter-Glo), Rhodamine 123 efflux, Western blot and RT-qPCR for ABCB1, flow cytometry for P-gp surface detection, intracellular drug accumulation, and RNA-seq transcriptomics. The ABCB1 Knockout Ca Ski Polyclonal Cells are an essential resource for cancer researchers and drug developers targeting efflux-mediated resistance. For further information, contact Ascent Research.
